Organon & Co.

OGNintermediary

Organon is a women's health-focused pharmaceutical company spun off from Merck in 2021, combining contraceptive and fertility products with a growing biosimilars portfolio.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($6.3B)

Datos estáticos (cargando finanzas en tiempo real…)

Women's Health (28%)

Biosimilars (18%)

Established Brands (54%)

Composición de segmentos y clientes principales

Detalles del producto

Nexplanon25%

Long-acting reversible contraceptive implant — #1 in its class

Fertility (Follistim, Ganirelix)15%

Hormone therapies for assisted reproduction

Biosimilars20%

Renflexis, Hadlima, and other biosimilar products

Established Brands40%

Legacy Merck products including Zetia, Nasonex, Cozaar

Relaciones en la Cadena de Suministro

Socios

Merck & Co.

Spun off from Merck in 2021

Impacto: Medium — legacy Merck product rights

Competidores

Viatris Inc.

Biosimilar market

Impacto: Medium — competing biosimilar portfolios

Clientes Clave

Walgreens Boots Alliance

Pharmacy retail distribution

Impacto: Low — indirect distribution

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Organon & Co. impulsado por IA.

Información de la Empresa

Sede Central

Jersey City, New Jersey, USA

Fundación

2021

Empleados

10,000+

Sitio Web

organon.com

Estado del sector — 제약 / 바이오

Noticias del sector